# FDA 483 - Salil U. Nadkarni, DO - September 24, 2021

Source: https://www.keypedia.com/records/483/salil-u-nadkarni-do/a5889bb1-6271-4fc5-9d54-b074deb7dddb

> FDA 483 for Salil U. Nadkarni, DO on September 24, 2021. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Salil U. Nadkarni, DO
- Inspection Date: 2021-09-24
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Salil U. Nadkarni, DO, a clinical investigator in Los Angeles, CA, revealed a significant deviation from the investigational plan. The firm failed to ensure subjects met the required compliance for completing headache diaries during screening, impacting subject eligibility for a clinical trial. This indicates a failure to conduct the investigation in accordance with the protocol.

## Related Officers

- [Julian C. Hanson](https://www.keypedia.com/people/julian-c-hanson/489e27d9-0de6-4bf0-8aec-e5d500841f52)

Company: https://www.keypedia.com/companies/salil-u-nadkarni-do/43a714f7-74c4-41b6-af5a-21def09d5d2c

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6